Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 5 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Allogene secures $15 million grant for cancer trial By Investing.com
Investing.com· 2 days agoThe funding is earmarked to support the Phase 1 TRAVERSE trial, which is evaluating the safety and...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
KLAS Las Vegas· 3 days agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 3 days agoThe NDA is supported by results from JUPITER...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Cancer drug trial provides lessons for future
Medical Xpress· 3 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 3 days agoKeytruda sales gained from rapid uptake across earlier-stage indications like triple-negative breast...
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 5 days agoMirae Asset Global Investments Co. Ltd. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.4% during the fourth quarter, according to its most recent 13F filing ...